Oncology

#Cancer research #Cell therapy #Drug development #Drug discovery #Oncology

New DDW Highlights podcast: 24 March 2025

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. This week the DDW news round-up takes a look at developments in cancer research,… Read More

#News

#Cancer research #Cell therapy #Drug development #Drug discovery #Oncology

This week in drug discovery (17-21 March) 

News round-up for 17-21 March by DDW Senior Digital Content Editor Diana Spencer. This week the DDW news round-up takes a look at developments in cancer research, including AZ’s acquisition of EsoBiotec, positive trial results for an allogeneic T-cell therapy, and a new drug target for glioblastoma. Read More

#News

#Oncology #Peptides #Transcriptomics #University of Bath

Promising drug candidates for previously ‘undruggable’ target

Reportedly for the first time, researchers from the University of Bath have identified  promising  drug candidates that bind irreversibly with a notoriously ‘undruggable’ cancer protein target, permanently blocking it. Transcription factors are proteins that act as ‘master switches’ of gene activity and play a key role in cancer… Read More

#Cancer Research #News #Trending News

T cells attacking cancer
#Cell therapy #Haematology #Oncology #Orca Bio #Phase III trial

Allogeneic T-cell therapy doubles rate of survival free from GvHD

Biotechnology company Orca Bio has revealed positive results from the Phase III Precision-T study of Orca-T, its lead investigational allogeneic T-cell immunotherapy, in patients with haematological malignancies.  The trial included patients with acute myeloid leukaemia (AML), acute lymphoblastic leukaemia (ALL), high-risk myelodysplastic syndrome (MDS) and mixed-phenotype acute… Read More

#Cancer Research #News #Trending News

Cancer cells
#Japan #Oncology #Phase II trial #Rare cancers

Dual approach could transform treatment of rare cancer

Researchers have combined immunotherapy and chemotherapy to offer new hope for patients with thymic carcinoma, a rare and aggressive cancer.  Thymic carcinoma is often associated with poor prognosis in advanced or recurrent stages. However, its rarity has delayed the development of novel pharmacotherapy.   Now, researchers… Read More

#Cancer Research #News #Trending News

#AI / data analytics / healthtech / informatics #Cancer research #DNA #Genetics / genomics #Oncology #RNA #siRNA

New podcast: The revolutionary impact of understanding genomics

This is the latest episode of the free DDW narrated podcast, titled “The revolutionary impact of understanding genomics”, which covers two articles written for DDW Volume 24 – Issue 3, Summer 2023. They are called: “Open science, genomics, and the quiet revolution in our approach to pharma” and “… Read More

#News

Ki67 staining
#Antibody drug conjugate (ADC) #Biospecimen collection #Monoclonal antibodies #Oncology

Advancing cancer therapy with antibody-drug conjugates

Cathie Miller, PhD, Senior Director of Product Marketing at BioIVT, discusses biospecimens and analytical techniques supporting the rapid evolution of ADCs in oncology. Antibody-drug conjugates (ADCs) are making significant strides forward as targeted cancer therapies. By coupling the specificity of antibodies with the potency of cytotoxic drugs, ADCs aim to… Read More

#Cancer Research #Exclusive Content

#Cancer Research UK #Gene mutation #Genetics / genomics #Oncology #Paediatrics #The Institute of Cancer Research

International team unlocks the genetic secrets of neuroblastoma

A team of international researchers have secured £1.5 ($1.9) million funding from Cancer Research UK (CRUK) to study the genetic secrets of childhood cancer neuroblastoma.  The project will be led by scientists at the University of Sheffield, alongside colleagues from The Institute of Cancer Research (ICR), Kings… Read More

#Cancer Research #News #Trending News

Pancreatic cancer
#Cancer drug targets #Gene mutation #Oncology #The Institute of Cancer Research

Algorithm identifies new potential targets for cancer drugs

Scientists have developed a tool which helps them better understand cancer’s survival tactics and could eventually lead to new treatments for dozens of cancers.  ‘Synthetic lethality’, the tactic of blocking pathways that cancer cells rely on, has so far mainly been successful in patients with BRCA-mutated breast,… Read More

#Cancer Research #News #Trending News

Antibody drug conjugate
#Antibody drug conjugate (ADC) #Callio Therapeutics #Financing #Oncology #Start-ups

$187m supports a new generation of ADC therapies

Biotechnology company Callio Therapeutics has announced its launch with the closing of a $187 million Series A financing round.   Callio is focused on realising the promise of multi-payload antibody-drug conjugates (ADCs) to improve cancer therapy.  The newly formed company, with headquarters in Seattle and Singapore,… Read More

#Business & Investment #Cancer Research #News #Start-up Zone

Oslo stock exchange
#Cell therapy #Celluna #Natural killer cells #Oncology #Solid tumours

First cell therapy company lists on the Oslo Stock Exchange

Zelluna, a developer of allogeneic ‘off the shelf’ T cell receptor based natural killer (TCR-NK) cells for the treatment of cancer, has announced the successful completion of a Business Combination and Private Placement on the Oslo Stock Exchange.  The share capital increases relating to the issuance of… Read More

#Business & Investment #News

CAR-T in multiple myeloma
#CAR-T #Cell therapy #Interview #Kite Pharma #Oncology

CAR-T cell therapy: Overcoming critical infrastructure challenges 

DDW’s Diana Spencer speaks to Dan Tovar, Senior Director, Head of Cell Therapy ACE Midsize Markets, Medical Affairs at Kite Pharma, about the current landscape for cell therapies and what can be done to improve patient access.  DS: Kite has pioneered cell therapy, with Yescarta (axicabtagene ciloleucel) as… Read More

#Business & Investment #Cancer Research #Exclusive Content

Doctor points at child's brain scan
#Australia #Brain cancer #Checkpoint inhibitor therapies #Immunotherapy #Oncology #University of Sydney

Study shows potential for triple immunotherapy in glioblastoma

An experimental cancer treatment developed by researchers at the Melanoma Institute Australia paves the way for a clinical trial to be conducted by researchers at the Brain Cancer Centre in Melbourne.  It is the first documented use of neoadjuvant triple immunotherapy in glioblastoma, involving a combination of… Read More

#Cancer Research #News #Trending News

#Eikon Therapeutics #Financing #Melanoma #Oncology

Eikon secures $350.7 million to advance oncology programmes

Eikon Therapeutics has announced the initial closing of a $350.7 million Series D financing, led by existing investors. Since its founding in 2019, the company has privately raised over $1.1 billion.  “Eikon has made remarkable progress in advancing a pivotal-stage clinical pipeline and early-stage development programme… Read More

#Business & Investment #News